n-heptyl D-glucopyranoside | 128052-80-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: n-heptyl D-glucopyranoside
• 英文别名: (3R,4S,5S,6R)-2-heptoxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 128052-80-2
• 化学式: C₁₃H₂₆O₆
• 分子量: 278.346
• InChiKey: NIDYWHLDTIVRJT-HENWMNBSSA-N

物化性质

• 熔点：
  76-78 °C
• 沸点：
  443.1±45.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  n-heptyl D-glucopyranoside 生成 (2R,3R,4R,5S)-6-heptoxyhexane-1,2,3,4,5-pentol
  参考文献：
  名称：

  Dahlhoff, Wilhelm V., Liebigs Annalen der Chemie, 1990, # 8, p. 811 - 813

  摘要：

  DOI：
• 作为产物：
  描述：

  D-葡萄糖 、 正庚醇 在 amyloglucosidase of Rhizopus mold 作用下， 以 异丙醚 、 acetate buffer 为溶剂， 反应 72.0h， 以19%的产率得到n-heptyl D-glucopyranoside
  参考文献：
  名称：

  Vijayakumar, Giriyapura R.; George, Charles; Divakar, Soundar, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 2, p. 314 - 319

  摘要：

  DOI：

文献信息

• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。
• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'UNE INFECTION À NOROVIRUS
  申请人：UNIV EMORY

  公开号：WO2017197377A1

  公开（公告）日：2017-11-16

  The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

  本发明涉及用于预防、治疗或治愈人类主体或其他动物宿主中的诺如病毒感染的化合物、组合物和方法。
• [EN] ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS<br/>[FR] ÉLIMINATION DU VIRUS DE L'HÉPATITE B PAR DES AGENTS ANTIVIRAUX
  申请人：UNIV EMORY

  公开号：WO2017156255A1

  公开（公告）日：2017-09-14

  The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

  本发明涉及用于预防、治疗或治愈人类或其他动物宿主体内乙型肝炎（HBV）感染的化合物、组合物和方法。这些化合物还包括作为药用的可接受的盐、前药和其他衍生物，以及用于治疗、预防或根除HBV感染的药物组合物和方法。
• PERFUMES IN THE FORM OF AQUEOUS MICROEMULSIONS
  申请人：CHANEL PARFUMS BEAUTE

  公开号：US20200323749A1

  公开（公告）日：2020-10-15

  Disclosed is a microemulsion of oil-in-water type including, preferably consisting of, by weight relative to the total weight of microemulsion: • 70% to 94% of water, • 1% to 15% of at least one hydrophobic fragrancing substance, • 4% to 20% of at least one preferably volatile solvo-surfactant, and • 0.1% to 15%, preferably 1% to 13%, of at least one hydrotropic agent or at least one surfactant selected from anionic surfactants, cationic surfactants, amphoteric surfactants and non-ionic surfactants. The solvo-surfactant is selected from monoalkylated glycerol derivatives of following formula (I): wherein the “alkyl” group is a linear or branched alkyl group including from 1 to 8 carbon atoms, and R and R′ are each independently H or a linear or branched alkyl group including from 1 to 5 carbon atoms, with the proviso that R is different from R′, and mixtures thereof.

  公开了一种油包水型微乳液，包括，相对于微乳液的总重量，优选包括： • 70%至94%的水， • 1%至15%的至少一种疏水香料物质， • 4%至20%的至少一种优选挥发性溶剂表面活性剂，以及 • 0.1%至15%，优选1%至13%的至少一种增溶剂或至少一种选择自阴离子表面活性剂、阳离子表面活性剂、两性表面活性剂和非离子表面活性剂的表面活性剂。溶剂表面活性剂选择自以下化学式（I）的单烷基甘油衍生物：其中“烷基”基团是包括1至8个碳原子的直链或支链烷基基团，R和R'各自独立地是H或包括1至5个碳原子的直链或支链烷基基团，但R与R'不同，并且它们的混合物。